Spectrascience New Stock Buy Hold or Sell Recommendation
| SCIE Stock | USD 0.000001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Spectrascience New is 'Strong Sell'. Macroaxis provides Spectrascience New buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SCIE positions.
Check out Spectrascience New Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide. Note, we conduct extensive research on individual companies such as Spectrascience and provide practical buy, sell, or hold advice based on investors' constraints. Spectrascience New. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Spectrascience |
Execute Spectrascience New Buy or Sell Advice
The Spectrascience recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Spectrascience New. Macroaxis does not own or have any residual interests in Spectrascience New or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Spectrascience New's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Spectrascience New Trading Alerts and Improvement Suggestions
| Spectrascience New generated a negative expected return over the last 90 days | |
| Spectrascience New has some characteristics of a very speculative penny stock | |
| Spectrascience New has high likelihood to experience some financial distress in the next 2 years | |
| Spectrascience New currently holds 6.38 M in liabilities. Spectrascience New has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Spectrascience New's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.15 K. Net Loss for the year was (4.47 M) with loss before overhead, payroll, taxes, and interest of (196.44 K). | |
| Spectrascience New currently holds about 27.88 K in cash with (1.51 M) of positive cash flow from operations. | |
| Spectrascience New has a frail financial position based on the latest SEC disclosures |
Spectrascience New Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Spectrascience New or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Spectrascience New's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Spectrascience stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Spectrascience New Volatility Alert
At this time Spectrascience New exhibits very low volatility. Spectrascience New appears to be a penny stock. Although Spectrascience New may be, in fact, a solid short-term or long term investment, many penny stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Spectrascience New or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Spectrascience instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Spectrascience New Fundamentals Vs Peers
Comparing Spectrascience New's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Spectrascience New's direct or indirect competition across all of the common fundamentals between Spectrascience New and the related equities. This way, we can detect undervalued stocks with similar characteristics as Spectrascience New or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Spectrascience New's fundamental indicators could also be used in its relative valuation, which is a method of valuing Spectrascience New by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Spectrascience New to competition |
| Fundamentals | Spectrascience New | Peer Average |
| Return On Asset | -0.92 | -0.14 |
| Current Valuation | 492.38 K | 16.62 B |
| Shares Outstanding | 4.92 B | 571.82 M |
| Price To Earning | (0.04) X | 28.72 X |
| Price To Sales | 73.07 X | 11.42 X |
| Revenue | 5.15 K | 9.43 B |
| Gross Profit | (196.44 K) | 27.38 B |
| EBITDA | (1.99 M) | 3.9 B |
| Net Income | (4.47 M) | 570.98 M |
| Cash And Equivalents | 27.88 K | 2.7 B |
| Total Debt | 6.38 M | 5.32 B |
| Current Ratio | 0.02 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (1.51 M) | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Number Of Employees | 5 | 18.84 K |
| Beta | -27.11 | -0.15 |
| Market Capitalization | 4.92 K | 19.03 B |
| Total Asset | 1.39 M | 29.47 B |
| Retained Earnings | (53.97 M) | 9.33 B |
| Working Capital | (10.5 M) | 1.48 B |
| Current Asset | 479 K | 9.34 B |
| Current Liabilities | 10.98 M | 7.9 B |
| Net Asset | 1.39 M |
Note: Acquisition by Miller Sheldon L of 100000 shares of Spectrascience New at 0.06 subject to Rule 16b-3 [view details]
Spectrascience New Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Spectrascience . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 9223372 T |
About Spectrascience New Buy or Sell Advice
When is the right time to buy or sell Spectrascience New? Buying financial instruments such as Spectrascience Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Spectrascience New in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Spectrascience New Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.